ProtoKinetix says AAGP protects against harsh radiation

By Elaine Rigoli

Tampa, Fla., July 12 - ProtoKinetix, Inc. announced that ongoing testing has resulted in a definitive confirmation of AAGP's ability to preserve living cells against harsh radiation.

The company said it completed a series of tests bombarding human skin cells with very strong radiation. After six hours of UV-C exposure, the control group (untreated) cells were irradiated to death.

However, using a 5 mg/ml concentration of AAGP on cells exposed to six hours of UV-C radiation, ProteoCell reported an 85% survival rate.

The company said these results demonstrate the strong protective effects of AAGP even after excessive UV-C treatment.

More advanced testing has started with major institutions to develop several medical applications for these molecules.

ProtoKinetix is a biotechnical company based in Vancouver, B.C.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.